The Half and Half X-Waiver Course | Office-Based Treatment for Opioid Use Disorders

The “Drug Addiction Treatment Act of 2000” created the opportunity to expand treatment for opioid use disorder into the mainstream of medical practice, increase the number of persons treated, and have an important positive public health impact. The legislation specifies several ways in which prescribers can be considered qualified to prescribe and dispense buprenorphine in their offices for the treatment of opioid use disorder. The completion of this training fulfills the requirement prior to notifying the U.S. Department of Health and Human Services (DHHS) of their intention to begin prescribing buprenorphine for the treatment of opioid use disorder.



The “Half and Half” course includes both online and face-to-face components. The first “half” of this course consists of 3.75 hours of self-guided online training, including five modules and a required examination. After completing the first “half” of the course and successfully passing the examination, you must attend the second “half” of the course. The second “half” of the course consists of 4.25 hours of live face-to-face training which takes place on August 11, 2017, at Maine Medical Center’s Dana Center, Room 4, Portland, Maine.

Information on accessing and completing the online portion of the training will be emailed upon registration for this event.

The online course and presentation are designed to train qualified physicians, physician assistants and nurse practitioners in dispensing or prescribing specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in an office-based setting. The goal of this training is to acquire the knowledge and skills needed to provide optimal care to opioid use disorder patients.

Designated by the DHHS, this training meets the eight-hour requirement and is designed for prescribers to dispense buprenorphine in office practice for treatment of opioid use disorder. Participation in this training will provide participants with a comprehensive overview of buprenorphine prescribing and its safe and effective use in an office-based setting. This training is designed for physicians, physician assistants and nurse practitioners and other primary care providers who are likely to treat opioid dependent persons in their practice, such as those in family practice, general internal medicine, psychiatry, pediatrics, adolescent medicine specialists, and Opioid Treatment Programs.

Prescribers other than physicians need an additional sixteen (16) hours of training. The additional 16 hours of training is available on at no cost.

Residents can take the waiver training, however they will not be able to apply until they have a personal DEA number and an unrestricted medical license. 


Dr. Kristin Silvia

Kristen B. Silvia, MD is the Primary Care Champion for Maine Medical Center’s new Integrated Medication Assisted Therapy (IMAT) Program. Dr. Silvia became interested in treating patients with substance use disorders while in residency and has been a provider of buprenorphine therapy for the treatment of opiate dependence to more than 120 patients over the past 10 years.

Dr. Leora Cohen-McKeon

Leora Cohen-McKeon, DO is a family medicine physician in Portland Maine at Martins Point Health Care. She has been practicing medicine since 2009. She has a specialty in women’s health care and provides care for opioid dependence. She has been prescribing buprenorphine for 7 years alongside her general medicine practice.


  • Maine Medical Center designates this educational activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Registration will begin at 7:45 a.m.


Funding for this conference was made possible (in part) by grant no. 5U79TI026556-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.